Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Explains How To Build COVID-19 Resilience Into Trial Design

Sponsors Can Use Existing Regulatory Flexibilities To Minimize Further Disruptions

Executive Summary

The UK Medicines and Healthcare products Regulatory Agency wants clinical trial sponsors to integrate available regulatory flexibilities into normal practice so that their studies can withstand further potential disruptions from the COVID-19 pandemic.

You may also be interested in...



UK MHRA: COVID-19 To Spark Rise In Clinical Trial-Related Deviations

The UK’s Medicines and Healthcare products Regulatory Agency says that any increase in clinical trial protocol deviations in relation to coronavirus outbreak will not constitute a serious breach.

Mandatory Use Of ‘Dysfunctional’ EU Clinical Trial Portal Raises Concern In Germany

Efforts are on to address the “serious deficiencies” raised by the German associations for medical ethics committees, trial sponsors, contract research organizations and other stakeholders regarding the EU Clinical Trial Information System that will become mandatory from 31 January 2023.

Global Pharma Guidance Tracker – November 2022

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS143285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel